|Bid||2.0500 x 800|
|Ask||2.0700 x 4000|
|Day's Range||2.0100 - 2.0700|
|52 Week Range||1.9600 - 4.4000|
|Beta (5Y Monthly)||2.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.67|
ROCKVILLE, Md., July 29, 2021--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Thursday, August 5, 2021, at 8:30 a.m. ET.
ROCKVILLE, Md., July 22, 2021--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the company’s lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML). The investigator-sponsored trial is being led by Tapan Kadia, M.D., associate professor of Leukemia at The University of Texas MD Anderson Cancer Center.
ROCKVILLE, Md., July 12, 2021--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at University of California (UC) Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit patients with treatment-naïve acute myeloid leukemia (AML). Brian A. Jonas, MD, PhD, FACP, UC Davis Division of Hematology/Oncology, is the clinical trial’s principal investigator.